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Edited by A MocanGlycolysis is a metabolic pathway vital to the production of energy and some organisms rely on it solely to meet
their energy requirements. It is also a central pathway in the metabolism of carbohydrates and a source of
therapeutic targets against diabetes and cancer. Caffeoylquinic acids (CQAs) have been extensively studied for
their role in the treatment and prevention of diabetes (and cancer) but theirmechanisms of action remainmostly
unknown. As such, molecular docking was used to find possible targets of CQAs in the glycolysis pathway. The
molecular docking assays showed that CQAs were docked preferably to the Rossman fold (nicotinamide adenine
dinucleotide — NAD(H) binding site) of oxidoreductases, that use NAD(H) as a cofactor, than to any other site.
In-vitro assays were then performed using two NAD(H) dependent oxidoreductases from glycolysis (alcohol
dehydrogenase and L-lactate dehydrogenase) in order confirm if CQAs would compete with the cofactor to
inhibit the reaction. The results from these assays indicate that CQAs can act as both inhibitors and activators
of NAD(H) dependent oxidoreductases of the glycolysis pathway.




In vitro kinetic assays
Glycolysis1. Introduction
Glycolysis was the first major metabolic pathway to be fully under-
stood (Lenzen, 2014). This pathway has many steps that ultimately
lead to the catabolism of glucose and other hexoses into pyruvate
(Pelicano et al., 2006; Bar-Even et al., 2012). Once pyruvate is produced,
the pathway diverges depending on the availability of oxygen. If it is
available, pyruvate molecules are oxidized to carbon dioxide and
water. If oxygen is not available, pyruvate is reduced to lactic acid. By
reducing pyruvate, NADH (nicotinamide adenine dinucleotide) is con-
verted to NAD+ (Pelicano et al., 2006; Bolaños et al., 2010; Bar-Even
et al., 2012). NAD+ is a cofactor for many of the enzymes in glycolysis
such as alcohol dehydrogenase (EC 1.1.1.1), aldehyde dehydrogenase
(EC 1.2.1.5) and glyceraldehyde 3-phosphate dehydrogenase (EC
1.2.1.12). Some enzymes use nicotinamide adenine dinucleotide
phosphate (NADP(H)) instead of NAD+ but both have the same
function (Bolaños et al., 2010). The complete glycolysis pathway,
as well as its connections to other metabolic pathways, can be seen
in Fig. 1.
Not all enzymes present in Fig. 1 are expressed in humans and in
some cases where there are several enzymes for a single reaction, the
enzymes belong to different cell types. As an example, the reaction
that converts α-D-glucose to α-D-glucose-6-phosphate is catalyzed by
two enzymes for eukaryotes (2.7.1.1 and 2.7.1.2) and two enzymes for
Archaea bacteria (2.7.1.63 and 2.7.1.147).hts reserved.As this work belongs to a larger project, in which one of the goals is
to findnew treatments andmolecular targets for Diabetesmellitus, only
enzymes expressed in humans were considered for evaluation through
the methods described on this manuscript.
1.1. Enzymes
1.1.1. EC 1.1.1.1 – Alcohol dehydrogenase
Alcohol dehydrogenase (ADH) is an enzyme that belongs to the
medium-chain dehydrogenase/reductases (MDR) super family. It is a
zinc containing MDR expressed by nine different genes in the human
genome to form five classes of ADHs (I to V). Classes I and II are found
mainly in the liver (Niederhut et al., 2001; Venkataramaiah and Plapp,
2003). Class I ADHs account for three of these genes due to the encoding
of three different subunits: α or A which is the only one expressed
during the fetal phase, β or B whose expression begins before birth
and γ or C which is expressed after birth (Niederhut et al., 2001). The
subunits encoded by these genes can form homo or heterodimers
while classes II through V only form homodimers (Niederhut et al.,
2001). This makes ADH the most common MDR in humans (Nordling
et al., 2002a, 2002b). In ADHs a distinction is also made between Class
III and non-Class III enzymes as the former are formaldehyde-active
while the latter are ethanol-active (Niederhut et al., 2001; Nordling
et al., 2002a, 2002b). An increased activity of Class III isoenzymes is
found in patients with pancreatic cancer (Jelski et al., 2014) and pancre-
atitis (Jelski et al., 2011). Heavy drinkers with either of these conditions
will also exhibit a higher activity of Class I ADH.
The activity of ADH can be reduced through several common
medications such as aspirin (acetylsalicylic acid) and salicylic acid
Fig. 1. The glycolysis metabolic pathway from KEGG (Ogata et al., 1999; Kanehisa et al., 2016, 2017).
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cimetidine (Lai et al., 2013). Of the four compounds, the one that affects
the catalytic activity of Class II ADH the most is cimetidine. With a con-
centration of 1 mM, cimetidine inhibited the activity by approximately
75% at 50 mM of ethanol.
Formamides are also effective inhibitors of ADH enzymes as
they mimic their aldehyde products. However, formamides act through
non-competitive inhibition against alcohols, allowing them to inhibit
ADHs even in high concentrations of alcohols (Venkataramaiah
and Plapp, 2003; Gibbons and Hurley, 2004). Haseba and colleagues
(Haseba et al., 2008), also studied the inhibition of ADHs (in mice)
using polyphenols present in whisky and found that vanillin,
syringaldehyde and ellagic acid inhibit ADH class I through mixed inhi-
bition while caffeic acid inhibited it through competitive inhibition.
Caffeic acid, performed the best out of these four compounds with an
inhibition constant of 0.08 μmol/L while pyrazone, a well-documented
inhibitor of ADH had an inhibition constant of 5.1 μmol/L. Additionally,
Cao and colleagues (Cao et al., 2010) report that ADH from Lactococcus
lactis is competitively inhibited by both ATP and ADP with a synergetic
effect between the two molecules and hypothesize that this inhibition
serves as a regulatory mechanism in the production of ATP.1.1.2. EC 1.1.1.27 — L-lactate dehydrogenase
L-lactate dehydrogenase (LDH — EC 1.1.1.27) is responsible for
converting lactic acid to pyruvate and vice-versa using NAD+ or NADH
as a cofactor. Its catalytic mechanism has been studied in depth and oc-
curs in three stages, the first stage involves the binding of the cofactor,
followed by the binding of the substrate and the mechanism is con-
cluded by the closure of the active site (Quaytman and Schwartz,
2009). Despite having a well-defined mechanism, the order of the
several transition states and chemical steps varies depending on the
organism (Quaytman and Schwartz, 2009). Like ADH, LDH is inhibited
by ADP and ATP in L. lactis (Cao et al., 2010).
There are two genes that encode LDH, LDHA and LDHB. The proteins
expressed by these two genes form tetramers that vary from only LDHA
(isoenzyme LDH5) to only LDHB (isoenzyme LDH1). LDHA has a higher
affinity for pyruvate than LDHB and is expressed mainly in tissues that
perform glycolysis heavily such as skeletal muscles. LDH has become a
target in oncology treatment due to its over expression and increased
activity in cancer cells (Feron, 2009; Doherty and Cleveland, 2013).
The over stimulation of anaerobic glycolysis in cancer cells is known
as the Warburg effect (Feron, 2009; Doherty and Cleveland, 2013) de-
scribed by the first time in 1956 by Otto Warburg (Warburg, 1956).
This effect is driven by hypoxia that, can be induced by cancer cells in
healthy cells through the endocytosis of hydrogen peroxide (Doherty
and Cleveland, 2013). Lactate from hypoxic cancer cells is exported to
non-hypoxic cancer cells that oxidize it and complete aerobic respira-
tion. This symbiotic effect allows hypoxic cells to survive otherwise
apoptotic conditions (very low pH) and provides energy to all cancer
cells (Doherty and Cleveland, 2013). This increased rate of glycolysis is
favored instead of aerobic respiration despite the lower energy yield
since the conversion of lactate to pyruvate produces sufficient NAD+
to fuel glycolysis if glucose is available. This also allows cancer cells
to fuel the pentose phosphate and fatty acid synthesis pathways that
are pivotal for fast cellular replication (Feron, 2009; Doherty and
Cleveland, 2013). Lactic acid is also considered a bio-marker for
metastasis (Walenta and Mueller-Klieser, 2004).
Gossypol is a polyphenol extracted from cotton seedwhich has been
extensively studied for its male contraceptive properties. It is also
known that gossypol is a non-selective inhibitor of NAD(H) binding to
oxidoreductases and the inhibition of LDH-C which is expressed only
in the testes and sperm (Yu et al., 2001). Additionally, it has also been
studied as the starting point for several anti-malaria drugs since
Plasmodium falciparum relies heavily on LDH for energy production
(Conners et al., 2005; Wiwanitkit, 2007).2. Material and methods
In this work, molecular docking was used as a screening technique
to narrow down the number of potential molecular targets and to
predict the mechanism of inhibition to be tested later through in-vitro
tests. This is similar to the approach of Zengin et al. (2017) although
the authors used molecular docking after establishing inhibitory
potency in-vitro.
2.1. Molecular docking
The first step of this work was to determine which glycolysis en-
zymes (Fig. 1) are expressed in humans so that their crystal structure
files could be downloaded from the PDB database and prepared for
the docking assays. Of the 31 enzymes expressed in humans, 9 did
not have a structure file on the PDB data base when the molecular
docking assays were performed. Of the remaining 21, one of the
enzymes (EC 2.7.1.11) had a very poor resolution (6.0 Å) and as
such was not used.
The samemethodwas applied to all enzymes. Briefly, a holoenzyme
structure file was downloaded from the PDB database for each of the 20
enzymes studied. Each structure file was then prepared for docking
using AutoDock Tools (Morris et al., 2009). First, water molecules and
any other molecules/ligands were removed until only the enzyme
remained, hydrogen atoms were added and finally, charges were
assigned to each atom. The new structure was then saved so it that
could be used later for docking with AutoDock Vina (Trott and Olson,
2010). Then, the structure of any other ligands (cofactors, substrates,
products or inhibitors) from the crystal structure was isolated and
prepared for docking through the same method as the enzymes and
then saved individually.
Six caffeoylquinic acids (1,3-diCQA; 1,5-diCQA; 3,4-diCQA; 3,4-
diCQA; 4,5-diCQA and 5-CQA, Fig. 2) were also prepared for docking
using the same method described in a previous work of the group
(Serina et al., 2016). Briefly, the molecules were created and optimized
using the MM+ forcefield to an RMS below 0.01 kcal/mol. After the
optimization, each CQA molecule was prepared for docking through
the same procedure as the enzymes in AutoDock Tools.
Once all ligands (CQAs and ligands present in the enzyme crystal
structure) were prepared for docking, the first set of the molecular
docking experiments were performed (rigid targeted/localizedmolecu-
lar docking) using AutoDock Vina (Trott and Olson, 2010). On this set,
the docking search area was defined as a cube with 26 Å sides centered
at the center ofmass for each non-enzyme ligand from the crystal struc-
ture. The ligands from each enzyme's structure were redocked to their
site on the enzyme to evaluate their binding affinity. The affinity of
these ligands was only considered when their docked conformation
matched the conformation of the crystal structure. This affinity was
then used as a benchmark to evaluate the CQA's potential effect. This
was done for each chain of the enzyme in the file even if several chains
contained the same ligands. Then, each CQA was docked at all the
relevant sites for each enzyme (co-factor site, substrate/product site
and allosteric inhibitor/regulatory sites if present).
The second stage of the molecular docking studies was a series of
blind docks. In these experiments, each CQA was docked to the enzyme
but instead of limiting the docking search area to the area around the
target site, the docking area was expanded to encompass the entire
enzyme to verify if the CQAs would indeed bind to the target sites of
the enzyme. This step of the molecular docking assays removed any
bias from the results that might have arisen from docking the CQAs
directly to the target sites.
Finally, the CQAs that were docked to the same site on the first
two stages of the docking experiments were used in a third docking
stage, flexible docking. To establish the docking search area for
these calculations, the ligand from that site was selected in the orig-
inal crystal structure. Then, all enzyme atoms around 8 Å of the
Fig. 2. Caffeoylquinic acids studied in this paper.
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molecular interactions. At this point, the selection of enzyme atoms
was expanded to include the residue they belonged to. Finally, the
docking area was established as the volume capable of accommodat-
ing all the selected residues and allows their bonds to rotate while
remaining inside the search area.
During this third and final docking stage, the CQAs with the best
(most negative) affinity were docked at their best scoring site but
with flexible enzyme residues. This type of docking allows both the
ligand and the enzyme's bonds to rotate to achieve the best possible
conformation for both the enzyme (receptor) and the CQA (ligand).
Although extremely lengthy and resource intensive (over one week
for each CQA / site combination), this type of docking also provides
the most accurate results (closest to in-vivo/in-vitro conditions) as it
can rearrange the conformation of the receptor to better accommodate
to the presence of the ligand.
Due to the limited amount of diCQAs available, it would only be possi-
ble to use each diCQA for the kinetic assays of one enzyme. A third CQA, 5-
CQA was used on both assays as its availability was not as limited as the
diCQAs and it would serve as a relative benchmark since it always scored
the poorest of all CQAs in the molecular docking studies. As such, two en-
zymes thatwerepredicted tobe inhibitedbydifferent diCQAswere chosen
for the in-vitro assays (alcohol dehydrogenase and lactate dehydrogenase).
2.2. In-vitro assays
The in-vitro assays had two goals, the first was to validate the results
frommolecular docking through enzyme kinetic assays and the second
was to establish the IC50 of each CQA towards each enzyme. In the en-
zyme kinetic assays, the concentration of the cofactor or the substrate
was varied and the concentration of the CQA was maintained while in
the IC50 assays, the concentration of the cofactor and the substrate
were fixed and the concentration of CQA was varied.
While in the molecular docking, the enzymes studied were all from
humans, for the in-vitro assays the enzymes used were not from humans.
Although there are some small differences in the sequence and structure
between the human and non-human enzymes, considering that this is
mainly an exploratory study and that the predicted/target site of the com-
pounds is the highly conserved Rossman Fold (NAD(H) binding site),
these differences were considered minor and, non-human enzymes
were used in the in-vitro assays.
2.2.1. Alcohol dehydrogenase (EC 1.1.1.1)
2.2.1.1. Materials. Ethanol active alcohol dehydrogenase from
Saccharomyces cerevisiae, NAD+, 5-caffeoyquinic acid and bovine
serum albumin (BSA) was acquired from Sigma-Aldrich. Ethanol was
acquired from Fisher, disodium phosphate fromMerck and phosphoric
acid from DBH. Both 1,3 and 1,5-dicaffeoylquinic acids were acquired
from Chengdu Biopurity Phytochemicals.2.2.1.2. Method. The measurements of enzyme activity were per-
formed in a Perkin Elmer multilabel plate reader Victor 3 on 96
well cyclic olefin copolymer plates at 340 nm. Buffer solutions of 10
and 60 mM of disodium phosphate were prepared, and their pH
was reduced to 7.5 and 8.5 respectively with a solution of 8%
phosphoric acid. The 10 mM buffer was used to prepare the initial
concentrated enzyme solution (≈1 mg/mL) and the enzyme diluent
solution (0.1% BSA w/v) in 10 mM Na2HPO4 at pH 7.5. The concen-
trated enzyme solution was diluted (1:125) using the diluent
solution and was kept between 2 and 8 °C. The NAD+ and
caffeoylquinic acid solutions were also kept at this temperature
and were stable for long periods of time (over three weeks). The
method used is a slightly modified version of the protocol proposed
by Taber (Taber, 1998). Briefly, 100 μL of disodium phosphate buffer
at pH 8.5 (60 mM) was mixed with 0–8 μL of ethanol solution (3 M),
0–10 μL of NAD+ (15 mM), 0–40 μL of 1,3 or 1,5-di-caffeoylquinic
acid (0.25 mg/mL ≈ 0.48 mM) or 0–50 μL of 5-caffeoylquinic acid
(1 mM), 20 μL of diluted enzyme solution (approximately 5 U/mL)
and water to complete a volume of 300 μL. In all assays, the reaction
was started by adding the enzyme to each well and absorbance was
measured at 340 nm every minute for 10 min. For each variable
concentration (cofactor, substrate or CQA) there were seven repeti-
tion wells. Once the data was collected, the highest and the lowest
(absorbance) values of each concentration (set of seven wells)
were discarded. The average of the remaining five wells was
calculated and used as the absorbance for that concentration. The
velocity of the reaction was then calculated using the following
formula: A340 nmt2−A340 nmt1t2−t1 where t2 and t1 represent the time (in
this case 5 and 0 min) and where A340 nmt2 and A340 nmt1 represent
the average (n = 5) absorbance at time t2 and t1.
2.2.2. Lactate dehydrogenase (EC 1.1.1.27)
2.2.2.1. Materials. NAD+, 5-caffeoyquinic acid and bovine serum
albumin (BSA) were acquired from Sigma-Aldrich. Lactate dehydroge-
nase from rabbit muscle was acquired from Roche. Calcium lactate
pentahydrate, ethylenediaminetetraacetic acid dihydrate (EDTA) and
disodium phosphate were acquired from Merck. Phosphoric acid was
acquired from DBH and both 3,4 and 3,5-dicaffeoylquinic acids were
acquired from Chengdu Biopurity Phytochemicals.
2.2.2.2. Method. The measurements of enzyme activity were per-
formed in a Perkin Elmer multilabel plate reader Victor 3 on 96
well cyclic olefin copolymer plates at 340 nm. Buffer solutions of
200 and 100 mM of disodium phosphate were prepared, and their
pH was reduced to 8.5 and 7.5 respectively with a solution of 8%
phosphoric acid. The 100mM buffer was used to prepare the enzyme
solution (≈11 U/mL) with 0.1% BSA (w/v). The solution was kept
between 2 and 8 °C. The NAD+ and CQA solutions were also kept at
Fig. 3. A) 1,3-diCQA docked at NAD site of ADH; B) NAD binding from the crystal structure of ADH (PDB id: 1U3W); C) NAD (cyan) from the crystal structure of LDH (PDB id: 4M49) and
3,4-diCQA (red) docked at the NAD binding site of LDH. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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weeks). The method used is a slightly modified version of the protocol
proposed by Powers et al. (2007). Briefly, 100 μL of disodiumphosphate
buffer at pH 8.5 (200 mM) was mixed with 0–20 μL of calcium lactate
(50 mM) + EDTA (75 mM) solution, 0–10 μL of NAD+ (15 mM), 0–
40 μL of 1,3 or 1,5-di-caffeoylquinic acid (0.25 mg/mL) or 0–50 μL
of 5-caffeoylquinic acid (1 mM), 20 μL of enzyme solution and water
to complete a volume of 200 μL. In all assays, the reaction was started
by adding the enzyme to each well and absorbance was measured at
340 nm every minute for 10 min. For each variable concentration (co-
factor, substrate or CQA) there were seven repetition wells. Once the
data was collected, the highest and the lowest (absorbance) values of
each concentration (set of seven wells) were discarded. The average
of the remaining five wells was calculated and used as the absorbance
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the time (in this case 5 and 0 min) and where A340 nmt2 and A340 nmt1
represent the average (n = 5) absorbance at time t2 and t1.
EDTA was added to the calcium lactate solution to prevent
the formation of calcium pyrophosphates that precipitated
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Fig. 5. Average (n = 3) binding affinity of best scoring conformation of CQAs towards LDH (kcal/mol).
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other site on the enzyme. Considering the docking results and the
limited availability of diCQAs two enzymes of this type that were po-
tentially inhibited by different CQAs were chosen for the in-vitro
assays. The enzymes selected for in-vitro assays were alcohol dehy-
drogenase and lactate dehydrogenase. In Fig. 3, the binding of CQAs
to NAD+'s binding site is observable both for both enzymes studied
in this paper.Fig. 6.Effects of CQAsonADHandNAD+Kinetics: A)Reaction yieldwith varying concentration o
concentration of NAD+ (0.75–0.075 mM; 0.075 mM steps) on ADH with 120 mM of ethanol;
steps) on ADH with 120 mM of ethanol; D) Effects of 5-CQA with variable concentration of NAAs shown in Fig. 3(A and B), the carboxylic acid group from CQAs in-
teractswith the samepositively charged residues as thephosphate groups
from NAD(H) while the diphenol rings from the caffeic acid moieties
mimic the nicotinamide and adenine aromatic rings and establish hydro-
gen bonds with some of the same residues as the amides from NAD(H).
The average (n = 3) binding affinity for the best scoring conforma-
tion of each CQA regarding ADH and LDH as well as their respective
crystal structure ligands can be found in Figs. 4 and 5.f CQAswith 100mMof Ethanol and 1.5mMofNAD+; B) Effects of 1,3-diCQAwith variable
C) Effects of 1,5-diCQA with variable concentration of NAD+ (0.75–0.075 mM; 0.075 mM
D+ (0.75–0.075 mM; 0.075 mM steps) on ADH with 120 mM of ethanol.
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The kinetic data of each enzyme were recorded and represented
using Lineweaver-Burk plots (Lineweaver and Burk, 1934). This type
of plot represents the inverse of the reaction velocity over the inverse
of the concentration of studied substrate. This type of plot makes it
possible to identify themechanism of inhibition towards each substrate.
When the regressions of the data points intercept on the abscissa (xx or
horizontal axis) this means that inhibitor is non-competitive while, if
the interception is on the ordinate (yy or vertical axis) the inhibitor is
competitive regarding the substrate. If the interception is between the
ordinate and the abscissa, the inhibition is considered as mixed
(partially competitive and partially non-competitive) and if the regres-
sions of the data points are parallel there is no inhibition. Due to exper-
imental errors, the interception of the regressions for competitive and
non-competitive inhibitors does not always perfectly overlap with
the corresponding axis. Experimental errors can also lead to several
interception points instead of one.3.2.1. Alcohol dehydrogenase
One of the goals of the in-vitro assays was to measure the IC50 of
each CQA towards ADH (Fig. 6 - A) and to investigate their inhibition
mechanism. Due to the reduced amount of diCQAs, it was not possible
to establish their IC50. While 1,3-diCQA achieved an inhibition of ap-
proximately 17.7% with 0.05 mg/mL, 1,5-diCQA achieved an inhibition
of approximately 32.9% at the same concentration. On the other hand,
5-CQA acted as an activator. While the effects of 1,5-diCQA and 5-CQA
had a good regression coefficient (R2 N 0.96), 1,3-diCQA had an accept-
able regression coefficient (R2 N 0.82). Due to linearity between the con-
centration of the compounds and their effect on the yield of the reaction,Fig. 7. Effects of CQAs on ADH and ethanol Kinetics: A) Effects of 1,3-diCQAwith variable conce
diCQAwith variable concentration of ethanol (120–15mM; 15mM steps)with 0.75mMof NAD
with 0.75 mM of NAD+.it is possible to easily estimate the IC50 for the diCQA and the concentra-
tion of 5-CQA that increased the reaction yield by 50%.
Considering the data from Fig. 6— A) and the equation for the effect
of 5-CQA on the reaction yield (y = 2.8581x + 1.039), it is possible to
calculate that concentrations of approximately 0.16 and 0.336 mM can
increase the reaction's yield by 50 and 100% respectively.
Considering the equations for 1,3-diCQA and 1,5-diCQA (y = − 2,
0787x+ 1, 0568 and y= − 3, 0239x+ 0, 9785 respectively) it is pos-
sible to estimate that the IC50 for these compounds is approximately
0.268 mM for 1,3-diCQA and 0.158 mM for 1,5-diCQA.
When analyzing the initial assay of the effect of 1,3-diCQA on NAD+
kinetics (data not shown), there was good linearity at the tested con-
centrations (0, 0.025 and 0.05 mg/mL). However, the linear regressions
of each concentration intercepted each other in the first quadrant of the
Lineweaver–Burk plot. Furthermore, the linear regression for the lower
concentration of 1,3-diCQA had a higher slope than the higher concen-
tration of 1,3-diCQAwhichwould indicate that the lower concentration
had a stronger inhibitory effect on the reaction. These unexpected re-
sults were initially attributed to some form of experimental error and
the assay was repeated. The data from the repetition can be seen on
(Fig. 6— B). Once again, all linear regressions had a very good regression
coefficient (R2 N 0.95), intercepted in the first quadrant of the plot and
the regression for the lower concentration of 1,3-diCQA had a higher
slope that the higher concentration.
Unlike 1,3-diCQA, 0.05 mg/mL of 1,5-diCQA had a stronger
inhibitory effect (higher slope) than 0.025 mg/mL (Fig. 6 — C).
Additionally, the interception of the linear regressions is not a single
point. While the regressions for 0 and 0.025 mg/mL of 1,5-diCQA
intercept in the first quadrant the regressions for 0 and
0.05 mg/mL intercept in the second quadrant (characteristic of
mixed inhibition).ntration of ethanol (120–15 mM; 15 mM steps) with 0.75 mM of NAD+; B) Effects of 1,5-
+; C) Effects of 5-CQAwith variable concentration of ethanol (120–15mM; 15mM steps)
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(Fig. 6—D), the expected behavior is observed for increasing concentra-
tions of inhibitor.
Higher concentrations of 5-CQA led to a higher slope on the regres-
sion. However, the interception of the regressions is once again in the
first quadrant.
When evaluating the effects of these ligands with varying con-
centrations of ethanol, both 1,3 and 1,5-diCQA had a higher inhibi-
tory activity at 0.025 mg/mL than at 0.05 mg/mL (Fig. 7 — A and B
respectively).
In Fig. 7— A it is possible to observe that 0.025mg/mL has a stronger
inhibitory power (higher slope) than 0.05 mg/mL and that the intersec-
tions of the regressions happen in the first quadrant.
On Fig. 7 — B it is possible to observe that unlike with the varying
concentrations of NAD+, 0.05 mg/mL of 1,5-diCQA had a smaller inhib-
itory effect than 0.025 mg/mL when the concentration of ethanol was
varied and that the interception of the linear regressions is inside the
first quadrant.
The effects of 5-CQA (Fig. 7 — C) follow the patterns of 1,3 and 1,5-
diCQA with the lower concentration of 5-CQA having a higher slope.
3.2.2. Lactate dehydrogenase
The initial IC50 assays of lactate dehydrogenase using 3,4 and 3,5-
diCQA as inhibitors did not present an acceptable linearity (R2 N 0.8)
when increasing the concentration of CQA (data not shown).
Due to the limited quantity of diCQAs, it would not be possible
to perform new IC50 assays as well as the enzyme kinetics assays
with these two diCQAs. Considering the main goal of this study, the
kinetic assays were favored and the second set of IC50 assays was
not performed.Fig. 8. Effects of CQAs on LDH and NAD+ Kinetics: A) Effects of 3,4-diCQAwith variable concent
3,5-diCQA with variable concentration of NAD+ (0–0.75 mM; 0.075 mM steps) on LDH with 1
0.075 mM steps) on LDH with 10 mM of lactate.The effects of 3,4-diCQA on lactate dehydrogenase with a variable
concentration of NAD+ were unexpected (Fig. 8— A) as the lower con-
centration of diCQA reduced the slope of the regressionwhen compared
with the reaction without 3,4-diCQA.
It is also worth mentioning that the interception of the three
regressions is in the first quadrant. When this assay was repeated
(data not shown) the higher concentration of 3,4-diCQA caused a
decrease in the slope of the reaction while the lower concentration
of 3,4-diCQA caused an increase in the slope when compared to the
reaction without 3,4-diCQA. In addition, the interception of these
regressions was inside the second quadrant, characteristic of mixed
inhibition.
The effects of 3,5-diCQA on lactate dehydrogenase with a variable
concentration of NAD+ are shown in Fig. 8 — B. When observing Fig. 8
— B it is possible to see that an increase in the concentration of 3,5-
diCQA leads to an increase in the slope of the regression. It is also possi-
ble to observe that the two concentrations of 3,5-diCQA intercept the re-
gression of the uninhibited reaction at different points.While the lowest
concentration of 3,5-diCQA appears to exhibit competitive inhibition
(interception at the vertical axis), the highest concentration of 3,5-
diCQA intercepts the uninhibited reaction regression in the first quad-
rant. This behavior was also observed when this assay was repeated
(data not shown).
When studying the effects of 5-CQA on NAD+ kinetics (Fig. 8— C), it
is possible to observe once again uncharacteristic behavior. The highest
concentration of inhibitor led to a smaller increase in slope than the
lowest concentration of inhibitor.
The interception of all regressions lies in thefirst quadrant. However,
when repeating this assay (data not shown) it was not possible tomake
the same observations as the data points were too far scattered makingration of NAD+ (0–0.75 mM; 0.075mM steps) on LDHwith 10mM of lactate; B) Effects of
0 mM of lactate.; C) Effects of 5-CQA with variable concentration of NAD+ (0–0.75 mM;
227J. Serina et al. / South African Journal of Botany 120 (2019) 219–229it impossible to perform a linear regression with an acceptable regres-
sion coefficient (R2 N 0.8).
The results of 3,4-diCQA on lactate kinetics can be seen on Fig. 9 - A.
An increase in the concentration of 3,4-diCQA lowered the slope of the
regression.
When the assay was repeated (data not shown), the increase in CQA
concentration led to an increase in the slope of the regression when
compared to the uninhibited reaction. As for the interception of the re-
gressions, while the highest concentration of 3,4-diCQA still intercepted
the uninhibited reaction in the first quadrant, the lower concentration
of inhibitor exhibited competitive inhibition when considering experi-
mental error (interception very close to the vertical axis). However,
one of the main limitations of the repetition was that the regression
coefficient (R2) was worse and below par (R2 ≈ 0.71) for the measure-
ments where 3,4-diCQA was present.
When analyzing the effects of 3,5-diCQA on lactate kinetics
(Fig. 9 — B) the two concentrations of 3,5-diCQA exhibited different
behaviors. While the lowest concentration appeared to have no in-
hibitory power (regression parallel to the uninhibited reaction) the
highest concentration intercepted the uninhibited reaction's regres-
sion in the first quadrant. When the assay was repeated (data not
shown) the behavior of the lowest concentration of inhibitor was
replicated while the higher concentration of 3,5-diCQA exhibited a
negative slope which was attributed to some form of experimental
error and the assays were repeated a third time.
On the third repetition, both concentrations of inhibitor displayed
mixed inhibition mechanism and the lower concentration of 3,5-
diCQA had a smaller slope than the uninhibited reaction (data not
shown).
Of all CQAs, 5-CQA was the least reproducible and had the worse
regression coefficients for the reaction with CQA present (Fig. 9 — C).Fig. 9. Effects of CQAs and oxalic acid on LDH and lactate Kinetics: A) Effects of 3,4-diCQAwith
B) Effects of 3,5-diCQAwith variable concentration of lactate (0–10mM;1mMsteps) on LDHw
1 mM steps) on LDH with 0.75 mM of NAD+; D) Effects of oxalic acid with a variable concentrIn Fig. 9 — C, the interceptions of the regressions are on the first
quadrant and the lowest concentration of 5-CQA caused a reduction in
the slope while the higher concentration of 5-CQA caused an increase
in the slope when compared to the reaction without 5-CQA. When
this assay was repeated (data not shown) it was not possible to repro-
duce the effect of the highest concentration of 5-CQA or to even observe
any linearity between the data points. The lowest concentration of
5-CQA still intercepted the uninhibited reaction in the first quadrant
but had a higher slope than it.
Considering the unexpected observations up to this point, the valid-
ity of the protocol being used was questioned. As such, a new assay
(Fig. 9 — D) was performed using oxalic acid (a known competitive
inhibitor towards lactate) instead of a CQA. The goal of this assay was
to find if the highly variable, hard to replicate behavior and results
were an artifact of the protocol.
From Fig. 9 — D, it is clear that oxalic acid competed with the sub-
strate (interception of the regressions with at or very close to the verti-
cal axis), the regression coefficient is excellent for both concentrations
of the inhibitor and, doubling the concentration of the inhibitor (from
10 to 20 mM) caused the slope to double as well. These results show
that the method being used is appropriate for this system.
4. Discussion
Most of the results from the kinetic assays showed that the regres-
sion of the reactionswhere CQAswere present intercepted the uninhib-
ited reactionwell inside the first quadrant of the Lineweaver-Burk plots.
Initially, this was attributed to some form of experimental error. This
meant that CQAs were acting as competitive inhibitors and that due to
the experimental errors the regressions were intercepting each other
in the first quadrant.variable concentration of lactate (0–10 mM; 1 mM steps) on LDHwith 0.75 mM of NAD+;
ith 0.75mMofNAD+; C) Effects of 5-CQAwith variable concentration of lactate (0–10mM;
ation of lactate (0–10 mM; 1 mM steps) on LDH with 0.75 mM of NAD+.
228 J. Serina et al. / South African Journal of Botany 120 (2019) 219–229However, this behavior was still observed when the assays were
repeated multiple times. Furthermore, while the cofactor and substrate
sites are connected in LDH, in ADH they are separated. As such the
hypothesis that the CQAs could compete with both molecules simulta-
neously was put aside. Masson et al. (Masson et al., 2008), studied
butyrylcholinesterase and encountered a ligand that produced a similar
Lineweaver-Burk plot to the ones from this work. According to the
authors, this is a special case where the ligand can act as an inhibitor
at low concentrations of the substrate but as an activator at high
concentrations of the substrate. This mechanism of action would
explain how CQAs are able to have a very high inhibitory effect in
some enzymes of the carbohydrate metabolism with very low toxicity
on healthy cells.
Nonetheless, it is imperative to recognize that this is merely an ex-
ploratory study of this topic and that further research is required. One
of the main issues to overcome on further work is the method used to
measure enzymatic activity/reaction progress. The caffeic acid moiety
of CQAs has an absorption maximum at 325 nm that tails off up to ap-
proximately 360 nm (Spagnol et al., 2015). This inevitably interferes
with the wavelength used to measure the concentration of NAD
(H) and the reaction progress in these assays (340 nm). Even though
the amount of available diCQAs was a limiting factor, the UV absorption
of the caffeic acid moiety also limited the concentrations of diCQAs that
could be used. Ideally, the reaction progress/quantification of each
compound should be performed through chromatographic methods
(HP/UP-LC). However, this might not always be feasible or available
(as in our case) since the assay mix includes buffers, the enzyme and
other components that are not usually safe to analyze using HP/UP-LC
methods.
In summary, diCQAs appear to function as activators and inhibitors
of NAD(P) dependent oxidoreductases of the glycolysis pathway. This
mechanism of action appears to depend on their concentration and
which isomer of diCQAs is being used. X-ray crystallography should be
used to produce structures of these enzymes in the presence of CQAs
to confirm their binding sites. Finally, more sophisticated quantification
methods should be favored over simple spectroscopic methods due to
the overlap in absorption peaks of NAD(P) with CQAs.Acknowledgements
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